MX2009013335A - Derivados de piperidina/piperazina. - Google Patents
Derivados de piperidina/piperazina.Info
- Publication number
- MX2009013335A MX2009013335A MX2009013335A MX2009013335A MX2009013335A MX 2009013335 A MX2009013335 A MX 2009013335A MX 2009013335 A MX2009013335 A MX 2009013335A MX 2009013335 A MX2009013335 A MX 2009013335A MX 2009013335 A MX2009013335 A MX 2009013335A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- aryl
- compounds
- 4alkyloxy
- 6alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/38—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/21—Radicals derived from sulfur analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Abstract
La invención se refiere a un inhibidor de DGAT de fórmula (I): (ver fórmula (I)) que incluye cualquier forma estereoquímicamente isomérica del mismo, en donde A representa CH o N; la línea punteada representa un enlace opcional en el caso en que A represente un átomo de carbono; X representa -C(=O)-; -O-C(=O)-; -C(=O)-C(O)-; -NRX-C(O)-; -Z1-C(=O)-; -Z1-NRx-C(=O)-; -C(=O)-Z1-; -NRx-C(O)-Z1-; -S(=O)p-; -C(=S)-; -NRX-C(=S)-; -Z1-C(=S)-; -Z1-NRX-C(=S)-; -C(=S)-Z1-; -NRx-C(S)-Z-; Y representa NRX- C(0)-Z2-; -NRX-C(0)-Z2-NRY-; -NRx-C(=O)-Z2-NRY-C(=O) -NRx C(=O)-Z2 NR'-C(=O)-O-; -NR'-C(=O)-Z2-O-; -NRX-C(=O)-Z2-O-C(0)-; -NRxC(=O)-Z2-C(=O)-; -NRxC(=O)-Z2-C(O)-O-; -NRX-C(=O)-O-Z2- C(=O)-; -NRxC(=O)-O-Z2-C(O)-O-; -NRx-C(=O)-OZ2-O-C(O)-; - NRX-C(=O)-Z2-C(=O)-NRSI-; -NRx-C(=O)-Z2-NR-C(=O)-NRf-; -C(=O)- Z2-; -C(=O)-Z2-O-; -C(=O)-NRX-Z2-; -C(=O)-NRX-Z2-O-; -CQO)-NRx- Z2-C(=O)-O-; -C(O)-NRx-Z2-O-C(O) -C(0)-NRX-O-Z2-; -C(=O)- NRx-Z2-NR-; -C(=O)-NR'-Z2-NR'--C(=O)-; -C(=O)-NRx-Z2-NRY-C(0)-O-; R' representa alquilo de C1-12 opcionalmente sustituido con ciano, alquiloxi de C1., alquilo de C1-oxi alquiloxi de C1, cicloalquilo de C o arilo; alquenilo de C2 alquinilo de C2 cicloalquilo de C adamantanilo; arilo1 aril1alquilo de C1 Het'; o Het alquilo de C1 con la salvedad de que cuando Y representa -NRX-C(=O)-Z2-; -NRX-C(=O)-Z2-N R -N RxC(=O)- Z2-C(=O)-NR'-; -C(=O)-Z2-; -NRx-C(=O)-Z2-NR-C(O)-NRf-; -C(0)- NRX-Z2-; -C(0)-NRX-O-Z2-; o -C(O)-NRx-Z2-NRf-; entonces R' puede también representar hidrógeno; R2 representa hidrógeno, alquilo de C1...,2, alquenilo de C o R3 con la salvedad de que si X representa -O-C(0)-, entonces R2 representa R3 y con la salvedad de que (A) se excluye; un N- óxido de los mismos, una sal farmacéuticamente aceptable de los mismos o un solvato de los mismos; además, la invención se refiere a métodos para preparar dichos compuestos, composiciones farmacéuticas que comprenden dichos compuestos así como al uso como un medicamento de dichos compuestos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07109868 | 2007-06-08 | ||
EP07115805 | 2007-09-06 | ||
PCT/EP2008/057060 WO2008148868A1 (en) | 2007-06-08 | 2008-06-06 | Piperidine/piperazine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009013335A true MX2009013335A (es) | 2010-01-20 |
Family
ID=39865125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009013335A MX2009013335A (es) | 2007-06-08 | 2008-06-06 | Derivados de piperidina/piperazina. |
Country Status (16)
Country | Link |
---|---|
US (1) | US8981094B2 (es) |
EP (1) | EP2152270B1 (es) |
JP (1) | JP5385263B2 (es) |
CN (1) | CN101678019B (es) |
AR (1) | AR066911A1 (es) |
AU (1) | AU2008258487B2 (es) |
BR (1) | BRPI0813331A2 (es) |
CA (1) | CA2687754C (es) |
CL (1) | CL2008001671A1 (es) |
ES (1) | ES2536406T3 (es) |
MX (1) | MX2009013335A (es) |
PA (1) | PA8783601A1 (es) |
PE (1) | PE20090362A1 (es) |
RU (1) | RU2470017C2 (es) |
TW (1) | TWI426070B (es) |
WO (1) | WO2008148868A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
EP1833806A1 (en) | 2004-12-14 | 2007-09-19 | AstraZeneca AB | Oxadiazole derivatives as dgat inhibitors |
US7749997B2 (en) | 2005-12-22 | 2010-07-06 | Astrazeneca Ab | Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors |
CA2647819C (en) | 2006-03-31 | 2012-12-11 | Novartis Ag | Phenylcyclohexyl derivatives as dgat1 inhibitors |
US8084478B2 (en) | 2006-05-30 | 2011-12-27 | Asstrazeneca Ab | Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase |
AU2008258549B2 (en) | 2007-06-08 | 2013-11-14 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
CA2687754C (en) | 2007-06-08 | 2015-12-08 | Janssen Pharmaceutica N.V. | Piperidine, piperazine derivatives for use as dgat inhibitors |
WO2008148851A1 (en) | 2007-06-08 | 2008-12-11 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
WO2009147170A2 (en) | 2008-06-05 | 2009-12-10 | Janssen Pharmaceutica Nv | Drug combinations comprising a dgat inhibitor and a ppar-agonist |
US9012159B2 (en) | 2009-02-04 | 2015-04-21 | Janssen Research & Development, Llc | Cell based screening assays for the triglyceride synthesis pathway |
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
CN106659765B (zh) | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
WO2016036638A1 (en) * | 2014-09-05 | 2016-03-10 | Merck Sharp & Dohme Corp. | Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
EP3393245A1 (en) | 2015-12-22 | 2018-10-31 | Syngenta Participations AG | Pesticidally active pyrazole derivatives |
MY195528A (en) | 2016-03-17 | 2023-01-30 | Hoffmann La Roche | 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar |
CN108250185B (zh) * | 2018-01-24 | 2020-08-21 | 浙江工业大学 | 6-(2-(邻甲苯氨基)乙酰氨基)喹唑啉类化合物及制备和应用 |
CN109438252B (zh) * | 2018-12-27 | 2021-12-14 | 安徽工业大学科技园有限公司 | 一种三(2-氨基乙基)胺的合成工艺 |
CN109516919B (zh) * | 2018-12-27 | 2021-12-14 | 安徽工业大学科技园有限公司 | 一种三(2-氨基乙基)胺的制备方法 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1383906A (en) | 1971-02-22 | 1974-02-12 | Bdh Pharmaceuticals Ltd | Pyridazinones |
JPS5692887A (en) | 1979-12-05 | 1981-07-27 | Sumitomo Chem Co Ltd | N-substituted imidazole derivative |
DE3338846A1 (de) | 1982-10-29 | 1984-05-03 | Toyama Chemical Co. Ltd., Tokyo | Neue 4-oxo-1,4-dihydronicotinsaeurederivate und salze derselben, verfahren zu ihrer herstellung und antibakterielle mittel mit einem gehalt derselben |
GB8729083D0 (en) | 1987-12-12 | 1988-01-27 | Pfizer Ltd | Triazole antifungal agents |
JP2969359B2 (ja) * | 1989-01-13 | 1999-11-02 | 武田薬品工業株式会社 | 環状アミン化合物 |
DE4317093A1 (de) | 1993-05-21 | 1994-11-24 | Basf Ag | Niedermolekulare und polymere flüssigkristalline Benztriazole und deren Verwendung |
TW286317B (es) | 1993-12-13 | 1996-09-21 | Hoffmann La Roche | |
US5639754A (en) | 1994-07-12 | 1997-06-17 | Janssen Pharmaceutica N.V. | Urea and thiourea derivatives of azolones |
US5637592A (en) | 1994-07-12 | 1997-06-10 | Janssen Pharmaceutica N.V. | Acyl derivatives of azolones |
FR2722788B1 (fr) * | 1994-07-20 | 1996-10-04 | Pf Medicament | Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant |
PL183865B1 (pl) * | 1995-01-11 | 2002-07-31 | Samjin Pharmaceutical Co | Nowe pochodne piperazyny i środek farmaceutyczny |
JP3294616B2 (ja) | 1995-08-10 | 2002-06-24 | メルク エンド カンパニー インコーポレーテッド | 2−置換アリールピロール、このような化合物を含む組成物及び使用方法 |
EP0871444A4 (en) | 1995-08-10 | 1999-01-13 | Merck & Co Inc | 2.5 SUBSTITUTED ARYL PYRROL, THE COMPOSITIONS THAT CONTAIN AND THE USE THEREOF |
GB9702213D0 (en) | 1996-02-24 | 1997-03-26 | Zeneca Ltd | Chemical compounds |
HN1997000027A (es) | 1996-12-06 | 1997-06-05 | Pfizer Prod Inc | Derivados de 6-fenil piridil - 2 amina |
JPH11139969A (ja) | 1997-08-07 | 1999-05-25 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
DE19743435A1 (de) | 1997-10-01 | 1999-04-08 | Merck Patent Gmbh | Benzamidinderivate |
KR20010070997A (ko) | 1998-07-20 | 2001-07-28 | 플레믹 크리스티안 | 비페닐 유도체 |
GB9826412D0 (en) | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
AUPP999799A0 (en) | 1999-04-27 | 1999-05-20 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
EA200101110A1 (ru) | 1999-05-21 | 2002-08-29 | Пфайзер Продактс Инк. | Новые фармацевтические комбинации ингибиторов nos |
WO2000078728A1 (en) | 1999-06-22 | 2000-12-28 | Neurosearch A/S | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
EP1263742B1 (en) | 2000-02-10 | 2005-08-24 | Pharmacia & Upjohn Company LLC | Oxazolidinone thioamides with piperazine amide substituents |
GB0013378D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
WO2001095856A2 (en) | 2000-06-15 | 2001-12-20 | Chaconne Nsi Co., Ltd. | Urea derivative useful as an anti-cancer agent and process for preparing same |
US20030060472A1 (en) * | 2000-06-21 | 2003-03-27 | Learmonth David Alexander | Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
GB2363792A (en) | 2000-06-21 | 2002-01-09 | Portela & Ca Sa | Nitrocatechols |
JO2654B1 (en) | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
DE10063008A1 (de) * | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
AU2002217742B2 (en) | 2001-01-16 | 2008-02-21 | Astrazeneca Ab | Therapeutic heterocyclic compounds |
JO2390B1 (en) | 2001-04-06 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Diphenylcarboxamides act as lipid-lowering agents |
DE10204116A1 (de) | 2002-02-01 | 2003-08-07 | Bayer Cropscience Ag | DELTA·1·-Pyrroline |
CN101450934B (zh) | 2002-03-13 | 2012-10-10 | 詹森药业有限公司 | 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物 |
OA12790A (en) | 2002-03-13 | 2006-07-10 | Janssen Pharmaceutica Nv | New inhibitors of histone deacetylase. |
CA2478502A1 (en) | 2002-04-01 | 2003-10-09 | Cadila Healthcare Limited | Novel antiinfective compounds, process for their preparation and pharmaceutical compositions containing them |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
US7842693B2 (en) | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
US7217726B2 (en) | 2002-08-22 | 2007-05-15 | Orchid Chemicals & Pharmaceuticals Limited | Antibacterial agents |
RU2342388C2 (ru) * | 2002-11-22 | 2008-12-27 | Джапан Тобакко Инк. | Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием |
EP2308848A1 (en) | 2003-02-03 | 2011-04-13 | Janssen Pharmaceutica NV | Quinoline-derived amide modulators of vanilloid VR1 receptor |
US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
US20070099884A1 (en) | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
EP2287166A3 (en) | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
ES2297458T3 (es) | 2003-08-11 | 2008-05-01 | F. Hoffmann-La Roche Ag | Piperazina con grupo fenilo or-sustituido y su empleo como inhibidores de glyti. |
JP2005206492A (ja) | 2004-01-21 | 2005-08-04 | Sankyo Co Ltd | スルホンアミド化合物 |
AU2005209115A1 (en) * | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
JP4787529B2 (ja) | 2004-04-09 | 2011-10-05 | 大塚製薬株式会社 | 医薬組成物 |
EP1764360A4 (en) | 2004-07-02 | 2010-08-11 | Sankyo Co | UREA DERIVATIVE |
MX2007000791A (es) | 2004-08-03 | 2007-03-23 | Wyeth Corp | Indazoles utiles en el tratamiento de enfermedades cardiovasculares. |
CN100360525C (zh) | 2004-09-16 | 2008-01-09 | 中国科学院上海药物研究所 | 一类新的噁唑烷酮衍生物、其制备方法和用途 |
CN101084207A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途 |
GB0421908D0 (en) | 2004-10-01 | 2004-11-03 | Angeletti P Ist Richerche Bio | New uses |
BRPI0516483A (pt) | 2004-10-15 | 2008-09-02 | Bayer Pharmaceuticals Corp | preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade |
AU2005299837A1 (en) | 2004-10-22 | 2006-05-04 | Janssen Pharmaceutica, N.V. | Inhibitors of c-fms kinase |
EP1833806A1 (en) | 2004-12-14 | 2007-09-19 | AstraZeneca AB | Oxadiazole derivatives as dgat inhibitors |
CA2586477A1 (en) | 2004-12-22 | 2006-06-29 | Janssen Pharmaceutica N.V. | Diacylglycerol acyltransferase assay |
GT200600046A (es) | 2005-02-09 | 2006-09-25 | Terapia de combinacion | |
GB0505084D0 (en) | 2005-03-11 | 2005-04-20 | Glaxo Group Ltd | Compounds |
WO2006105127A2 (en) * | 2005-03-31 | 2006-10-05 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
EP1869052A1 (en) | 2005-04-06 | 2007-12-26 | AstraZeneca AB | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
MX2007013049A (es) | 2005-04-19 | 2008-01-11 | Bayer Pharmaceuticals Corp | Preparacion y uso de derivados de aril alquil acido para el tratamiento de la obesidad. |
JP2008543747A (ja) * | 2005-06-11 | 2008-12-04 | アストラゼネカ アクチボラグ | Dgat阻害剤としてのオキサジアゾール誘導体 |
TWI364292B (en) | 2005-06-30 | 2012-05-21 | Ipsen Pharma Sas | Glp-1 pharmaceutical compositions |
JP2007131584A (ja) * | 2005-11-11 | 2007-05-31 | Sankyo Co Ltd | 新規ベンゾオキサゾール誘導体 |
AU2006326815A1 (en) | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
US7749997B2 (en) | 2005-12-22 | 2010-07-06 | Astrazeneca Ab | Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors |
TW200804364A (en) | 2006-02-22 | 2008-01-16 | Boehringer Ingelheim Int | New compounds |
US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
WO2008003766A2 (en) | 2006-07-06 | 2008-01-10 | Boehringer Ingelheim International Gmbh | 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments |
EP1918285A1 (en) | 2006-11-03 | 2008-05-07 | Merck Sante | Diazepane-acetamide derivatives as selective 11beta-HSD1 inhibitors |
GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
MX2009012285A (es) | 2007-05-22 | 2009-12-15 | Via Pharmaceuticals Inc | Inhibidores de diacilglicerol aciltransferasa. |
WO2008148851A1 (en) * | 2007-06-08 | 2008-12-11 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
AU2008258549B2 (en) | 2007-06-08 | 2013-11-14 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
CA2687754C (en) | 2007-06-08 | 2015-12-08 | Janssen Pharmaceutica N.V. | Piperidine, piperazine derivatives for use as dgat inhibitors |
WO2009147170A2 (en) | 2008-06-05 | 2009-12-10 | Janssen Pharmaceutica Nv | Drug combinations comprising a dgat inhibitor and a ppar-agonist |
-
2008
- 2008-06-06 CA CA2687754A patent/CA2687754C/en active Active
- 2008-06-06 CL CL2008001671A patent/CL2008001671A1/es unknown
- 2008-06-06 EP EP08760634.9A patent/EP2152270B1/en active Active
- 2008-06-06 BR BRPI0813331-0A2A patent/BRPI0813331A2/pt not_active Application Discontinuation
- 2008-06-06 AU AU2008258487A patent/AU2008258487B2/en not_active Ceased
- 2008-06-06 TW TW097121019A patent/TWI426070B/zh not_active IP Right Cessation
- 2008-06-06 AR ARP080102427A patent/AR066911A1/es unknown
- 2008-06-06 WO PCT/EP2008/057060 patent/WO2008148868A1/en active Application Filing
- 2008-06-06 CN CN200880019198.0A patent/CN101678019B/zh active Active
- 2008-06-06 ES ES08760634.9T patent/ES2536406T3/es active Active
- 2008-06-06 PA PA20088783601A patent/PA8783601A1/es unknown
- 2008-06-06 MX MX2009013335A patent/MX2009013335A/es active IP Right Grant
- 2008-06-06 RU RU2009148320/04A patent/RU2470017C2/ru active
- 2008-06-06 US US12/663,013 patent/US8981094B2/en active Active
- 2008-06-06 PE PE2008000972A patent/PE20090362A1/es not_active Application Discontinuation
- 2008-06-06 JP JP2010510816A patent/JP5385263B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
PA8783601A1 (es) | 2009-01-23 |
JP2010529089A (ja) | 2010-08-26 |
AU2008258487A1 (en) | 2008-12-11 |
CN101678019B (zh) | 2016-03-30 |
RU2470017C2 (ru) | 2012-12-20 |
TW200911771A (en) | 2009-03-16 |
RU2009148320A (ru) | 2011-07-20 |
CN101678019A (zh) | 2010-03-24 |
EP2152270A1 (en) | 2010-02-17 |
TWI426070B (zh) | 2014-02-11 |
CL2008001671A1 (es) | 2009-07-17 |
AU2008258487B2 (en) | 2012-11-15 |
AR066911A1 (es) | 2009-09-23 |
PE20090362A1 (es) | 2009-04-04 |
BRPI0813331A2 (pt) | 2014-12-23 |
JP5385263B2 (ja) | 2014-01-08 |
WO2008148868A1 (en) | 2008-12-11 |
EP2152270B1 (en) | 2015-03-04 |
US8981094B2 (en) | 2015-03-17 |
ES2536406T3 (es) | 2015-05-25 |
CA2687754A1 (en) | 2008-12-11 |
US20100190789A1 (en) | 2010-07-29 |
WO2008148868A8 (en) | 2009-03-05 |
CA2687754C (en) | 2015-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009013335A (es) | Derivados de piperidina/piperazina. | |
MX2009013334A (es) | Derivados de piperidina/piperazina. | |
CY1118292T1 (el) | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων | |
WO2008108386A1 (ja) | 医薬組成物 | |
CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
MX2009003939A (es) | Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes. | |
MX2008002061A (es) | Derivados de tiazolil piperidina utiles como moduladores del receptor h3. | |
NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
WO2007084914A3 (en) | Phenoxy-substituted pyrimidines as adenosine receptor antagonists | |
MX2010006882A (es) | Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica. | |
SI2091948T1 (sl) | Novi inhibitorji glutaminil ciklaze | |
TW200604175A (en) | Ortho substituted aryl or heteroaryl amide compounds | |
CO5150164A1 (es) | Derivados de pirazolopiridina | |
WO2008155668A3 (en) | Heteroarylamide pyrimidone compounds | |
MX2010000658A (es) | Derivados de pirimidina 934. | |
ATE476431T1 (de) | Piperidin- und azetidinderivate als glyt1- inhibitoren | |
NO20062255L (no) | 4-anilino-3-kinolinkarbonitriler for behandling av kronisk myelogenos leukemi (CML) | |
MX2010002584A (es) | Derivados de piperidina como agonistas de receptores muscarinicos. | |
TW200740795A (en) | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | |
ATE502936T1 (de) | 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten | |
MX2009002685A (es) | Derivados de acetamida de (2- (1-oxo-1h-isoquinolin-2-il). | |
MX2009012518A (es) | Derivados de piperidina 4,4-disubstituidos. | |
AR046753A1 (es) | Derivados de benzoxazina y usos de los mismos | |
TW200621227A (en) | Medicament for preventing or treating fatty liver | |
ATE406363T1 (de) | Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |